(165) Investigating the cardio-oncology patient population at a large, multi-site health system: a descriptive analysis

Poster Abstract:

Background: Cancer therapy related cardiac dysfunction (CTRCD) is a potential lifelong complication that can arise from cancer treatment. Ensuring optimal cardiovascular health before, during, and after therapy is essential to improve short- and long-term patient outcomes. This study aims to describe the cardio-oncology patient population and assess the incidence and management of cardiovascular complications associated with anti-cancer therapy in the adult population at a large health system. This study will contribute to the literature by providing insight into the current practices for the cardio-oncology patient population, which may inform clinical practice, expand access to care, and propel future research.

Objectives: To characterize the cardio-oncology patient population and evaluate the incidence of cardiovascular toxicities, the frequency of cardiac monitoring, and the management of cardiac dysfunction related to cancer treatment.

Methods: This is a retrospective, descriptive study conducted at a large, multi-site health system between June 1, 2020, and May 31, 2022. We will review the electronic health records of patients with cancer who received cardiotoxic anti-cancer (doxorubicin, trastuzumab, and pertuzumab) during the study period. Data collection will include patient demographics, cancer diagnosis and treatment, risk factors for heart failure, new consultations, echocardiogram results, prescribed heart failure guideline directed medical therapy, and hospitalizations due to heart failure. Descriptive statistics will be used to analyze and report the data.

Results: Results are pending and will be presented at the HOPA Annual Conference 2024 in Tampa, FL.

References (must also be included in final poster): 1. National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER Database. Accessed September 2, 2023.
2. Jafari L, Akhter N. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review. Breast Cancer Res Treat. 2021 Apr;186(2):295-303. doi: 10.1007/s10549-021-06096-9. Epub 2021 Jan 22.
3. Doxorubicin. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at https://online.lexi.com. Accessed September 5, 2023.
4. Trastuzumab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at https://online.lexi.com. Accessed September 5, 2023.
5. Pertuzumab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at https://online.lexi.com. Accessed September 5, 2023.
6. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3;79(17):e263-e421.
7. Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Mar 10;35(8):893-911.
8. Leong DP, Lenihan DJ. Clinical Practice Guidelines in Cardio-Oncology. Heart Fail Clin. 2022 Jul;18(3):489-501.
9. Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pract. 2021 May;17(5):228-236.
10. Pituskin E, Mackey JR, eta l. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017 Mar 10;35(8):870-877.
11. Esfandbod M, Naderi M, Sadatnaseri A, Ahmadi A, Noroozi M, Sadeghi Joni S. Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced HER2-Positive Breast Cancer Patients. Int J Hematol Oncol Stem Cell Res. 2021 Oct 1;15(4):206-212.
12. Livi L, Barletta G, Martella F, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1544-1549.
13. Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019 Jun;175(3):595-603.